Spruce Street Capital’s Alto Neuroscience ANRO Stock Holding History

Spruce Street Capital’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.7M	Buy	1,353,047 +27,837	+2%	+$644K	7.01%	5
2026 Q1	$29.1M	Buy	1,325,210 +1,102,366	+495%	+$20.4M	7%	6
2025 Q4	$3.97M	Buy	+222,844	New	+$2.81M	1.31%	21

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Spruce Street Capital's ANRO Position: Q2 2026 in Review

Spruce Street Capital increased its Alto Neuroscience (ANRO) stake by 2.1% in Q2 2026, buying an estimated $644K and bringing the position to 1,353,047 shares worth $35.7M. The position accounts for 7.01% of the portfolio, ranked #5.

Spruce Street Capital first reported a position in ANRO in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

Spruce Street Capital held 1,353,047 shares of Alto Neuroscience worth $35.7M as of Q2 2026.
Spruce Street Capital bought 27,837 Alto Neuroscience shares in Q2 2026, an estimated $644K.
Alto Neuroscience made up 7.01% of Spruce Street Capital's portfolio in Q2 2026, its #5 holding.
Spruce Street Capital first reported a position in Alto Neuroscience in Q4 2025 and has held it in 3 quarters since.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.